29 C
New York
Sunday, August 17, 2025

Tag: enrollment

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Centene Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – CNC

NEW YORK, Aug. 16, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Centene Corporation (NYSE: CNC) between December 12, 2024 and June 30, 2025, both dates inclusive (the “Class Period”), of the important September 8, 2025 lead plaintiff deadline.

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Centene

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Centene To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Reminds Investors of Novo, Altimmune, SelectQuote, and Spectrum that Lawsuits Have Been Filed and Encourages Investors to Contact the...

NEW YORK, Aug. 16, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Novo Nordisk A/S (NYSE:NVO), Altimmune, Inc. (NASDAQ:ALT), SelectQuote, Inc. (NYSE:SLQT) and Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SelectQuote

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In SelectQuote To Contact Him Directly To Discuss Their Options

Galvanize Announces First Patient Enrolled in the PROPEL Registry Evaluating Aliya® Pulsed Electric Field Ablation for Soft Tissue Lesions

Multicenter Registry Launches to Assess Real-World Outcomes and Clinical Integration of Nonthermal Aliya PEF Ablation REDWOOD CITY, Calif., Aug. 15, 2025 /PRNewswire/ -- Galvanize Therapeutics...

Ryght AI Partners with Global CRO Biorasi to Deliver AI-Powered Feasibility Solutions to Biotech and Biopharma Sponsors

Advanced AI Platform Enables More Accurate Site Selection and Faster Study Startup Across Key Therapeutic Areas Partnership brings real-time site identification, feasibility, activation and automated...

KinderCare Learning (KLC) Faces IPO Investor Securities Class Action Amid Claims of Child Neglect – Hagens Berman

SAN FRANCISCO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Gollapalli v. KinderCare Learning Companies, Inc., et al., No. 3:25-cv-01424 (D. Or.) has been filed and seeks to represent investors who purchased KinderCare (NYSE: KLC) common stock in or traceable to the company’s October 2024 IPO.

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

   
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial

CLEAR to Offer BOGO $15 Discount on TSA PreCheck® as Part of TSA’s “Families on the Fly” Campaign

NEW YORK, Aug. 15, 2025 (GLOBE NEWSWIRE) -- CLEAR (NYSE: YOU), an official TSA PreCheck® enrollment provider, is making it easier and more affordable for travelers to get through security faster. As part of the Transportation Security Administration’s (TSA) Families on the Fly campaign, CLEAR is offering a limited-time Buy One, Get One $15 Off promotion for TSA PreCheck® enrollment when two family members sign up together.

Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Carbon Streaming Announces Financial Results for the Three and Six Months Ended June 30, 2025

Carbon Streaming Announces Financial Results For The Three And Six Months Ended June 30, 2025

TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Completed the acquisition of Kineta, Inc. and its VISTA inhibiting monoclonal antibody (mAb), now named "TBS-2025;" planning to initiate a Phase 2 trial in...

Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights

- Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) - - Cash, cash equivalents, and marketable securities of $296.3...

Biotech Stocks Rally as Oncology Market Targets $866B by 2034

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- Equity Insider News Commentary – Despite alarming federal budget cuts...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsEnrollment